ERSPC, CAP, and ProtecT demonstrate PSA-detected prostate cancers have significant lead times, suggesting screening for prostate cancer may, on average, take 10–15 years or more to deliver meaningful benefits for men.6 Long acquisition times for new evidence poses additional challenges for health agencies making recommendations on screening. The gene discussed is KLK3; the disease is prostate carcinoma.